Pregnancy associated anemia and iron: a pilot study

Area of Science:

• Obstetrics and Gynecology
• Hematology
• Pharmacology

Background:

• Iron deficiency anemia is common during pregnancy, often treated with oral iron supplements.
• Poor patient compliance with iron therapy is frequently due to gastrointestinal side effects.
• Novel drug delivery systems aim to improve iron absorption and tolerability.

Purpose of the Study:

• To compare the efficacy and safety of a novel timed-release ferrous sulfate preparation (Code A) versus a sustained-release ferrous sulfate preparation (Code B) in pregnant anemic women.
• To evaluate iron absorption and subjective symptom improvement between the two formulations.
• To assess the non-compliance and dropout rates associated with each preparation.

Main Methods:

• A double-blind, randomized comparative study involving 60 pregnant women with anemia.
• Sequential randomization to receive either timed-release (Code A) or sustained-release (Code B) ferrous sulfate.
• Assessment of hemoglobin, serum iron, TIBC, ferritin levels, subjective symptoms, and side effects over 4 weeks.

Main Results:

• Both preparations showed a mean hemoglobin increase of approximately 2.0-2.3 gm% after 4 weeks.
• Timed-release ferrous sulfate (Code A) exhibited superior iron absorption, indicated by improvements in serum iron, TIBC, and ferritin.
• Sustained-release ferrous sulfate (Code B) showed better improvement in subjective symptoms of anemia; Code A had more side effects, contributing to a slightly higher dropout rate.

Conclusions:

• Timed-release ferrous sulfate offers comparable hematological response and enhanced iron absorption at significantly lower doses compared to sustained-release formulations.
• Despite a higher incidence of side effects, the timed-release preparation presents a promising alternative for managing iron deficiency anemia in pregnancy.
• Further research may optimize timed-release formulations to balance efficacy, absorption, and tolerability.